- Home
- CGTX vs NRXS Comparison
CGTX vs NRXS Comparison
Compare CGTX & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- NRXS
- Stock Information
- Founded
- CGTX 2007
- NRXS 2011
- Country
- CGTX United States
- NRXS United States
- Employees
- CGTX N/A
- NRXS N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- NRXS
- Sector
- CGTX Health Care
- NRXS
- Exchange
- CGTX Nasdaq
- NRXS Nasdaq
- Market Cap
- CGTX 17.9M
- NRXS 17.8M
- IPO Year
- CGTX 2021
- NRXS 2023
- Fundamental
- Price
- CGTX $0.43
- NRXS $2.19
- Analyst Decision
- CGTX Strong Buy
- NRXS
- Analyst Count
- CGTX 6
- NRXS 0
- Target Price
- CGTX $8.30
- NRXS N/A
- AVG Volume (30 Days)
- CGTX 2.8M
- NRXS 21.5K
- Earning Date
- CGTX 05-06-2025
- NRXS 04-08-2025
- Dividend Yield
- CGTX N/A
- NRXS N/A
- EPS Growth
- CGTX N/A
- NRXS N/A
- EPS
- CGTX N/A
- NRXS N/A
- Revenue
- CGTX N/A
- NRXS $2,456,219.00
- Revenue This Year
- CGTX N/A
- NRXS $383.16
- Revenue Next Year
- CGTX N/A
- NRXS N/A
- P/E Ratio
- CGTX N/A
- NRXS N/A
- Revenue Growth
- CGTX N/A
- NRXS N/A
- 52 Week Low
- CGTX $0.34
- NRXS $1.99
- 52 Week High
- CGTX $2.95
- NRXS $3.78
- Technical
- Relative Strength Index (RSI)
- CGTX 27.35
- NRXS 41.43
- Support Level
- CGTX $0.36
- NRXS $2.08
- Resistance Level
- CGTX $0.45
- NRXS $2.70
- Average True Range (ATR)
- CGTX 0.05
- NRXS 0.13
- MACD
- CGTX -0.01
- NRXS -0.00
- Stochastic Oscillator
- CGTX 23.66
- NRXS 28.17
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).